About Highline SCIENCES
Highline SCIENCES is a Healthcare company based in San Francisco (United States) founded in 2018, and was acquired by Tempus in February 2022. CRO focused on clinical development services for oncology drugs. Highline SCIENCES offers products and services including CRO Services and Consultancy Services. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Aster Insights, OnCusp and CancerVax; 3 of its 3 listed competitors have raised funding.
Company details
Highline Sciences was founded in 2018 and is headquartered in San Francisco, United States. As a contract research organization (CRO), focus is placed on clinical development services specifically for oncology drugs. Operations encompass trial design, regulatory support, and data management tailored to pharmaceutical partners in the biotechnology sector. Services are delivered across various phases of drug development, with an emphasis on oncology therapeutics in the North American market.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Website highlinesciences.com
- Acquired by Tempus (Feb 2022)
Products & Services of Highline SCIENCES
Highline SCIENCES offers a comprehensive portfolio of products and services, including CRO Services and Consultancy Services.
Full-service contract research for oncology biotech firms and clients.
Bespoke consultancy to address gaps in traditional biotech operations.
Investors in Highline SCIENCES
Highline SCIENCES has secured backing from 1 investor. Prominent investors backing the company include Tempus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
AI-based precision medicine solutions for oncology are provided. | 2015 | tempus.com | Chicago, United States |
Investor details for Highline SCIENCES
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Highline SCIENCES
3 people are tracked at Highline SCIENCES (1 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Collin Williams | Founder & Chief Executive Officer | Leadership |
Susan Refice | Clinical Project Manager | Team |
Eric Easter | Sr. Clinical Research Associate | Team |
Complete people profiles for Highline SCIENCES
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Highline SCIENCES
2 dated milestones of Highline SCIENCES across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Highline SCIENCES is founded.
- Exit Acquired by Tempus.
Competitors of Highline SCIENCES
Highline SCIENCES has 3 listed competitors in our database, 3 of them funded. They include Aster Insights, OnCusp and CancerVax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| asterinsights.com | 2006 | Tampa, United States | $75M | 115 | Contract-based oncology clinical trial services are provided by Aster Insights. | |
| oncusptx.com | 2021 | New York, United States | $100M | CRO offering clinical development services for oncology drugs | ||
| cancervax.com | 1998 | Carlsbad, United States | $55M | Cancer vaccine research and development is conducted by CancerVax. |
Detailed competitors of Highline SCIENCES
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Highline SCIENCES (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Highline Sciences
Complete news archive for Highline SCIENCES
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Highline SCIENCES
Highline SCIENCES was founded in 2018.
Highline SCIENCES is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Highline Sciences was founded in 2018 and is headquartered in San Francisco, United States. As a contract research organization (CRO), focus is placed on clinical development services specifically for oncology drugs. Operations encompass trial design, regulatory support, and data management tailored to pharmaceutical partners in the biotechnology sector. Services are delivered across various phases of drug development, with an emphasis on oncology therapeutics in the North American market.
Highline SCIENCES's top competitors include CancerVax, OnCusp and Aster Insights.
Highline SCIENCES offers CRO Services and Consultancy Services.
Highline SCIENCES has 1 investor. Key investors include Tempus.
Yes. Highline SCIENCES was acquired by Tempus in February 2022.

